Is robotic arm stereotactic body radiation therapy ‘virtual high-dose rate brachytherapy’ effective for prostate cancer? An analysis of comparative effectiveness using published data

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA. Cancer J Clin 2013;63(1):11-30
   PubMed Web of Science ®Google Scholar
• Zaorsky NG, Doyle LA, Hurwitz MD, et al. Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate cancer? Expert Rev Anticancer Ther 2014;14(1):39-50
   Google Scholar
• Zaorsky NG, Doyle LA, Yamoah K, et al. High dose rate brachytherapy boost for prostate cancer: a systematic review. Cancer Treat Rev 2014;40(3):414-25
   PubMed Web of Science ®Google Scholar
• Fuller DB, Naitoh J, Lee C, et al. Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations. Int J Radiat Oncol Biol Phys 2008;70(5):1588-97
   PubMed Web of Science ®Google Scholar
• Fuller DB, Shirazi R, Naitoh J, Mardirossian G. Virtual HDR SBRT for localized prostate carcinoma: Efficacy and quality-of-life assessment. J Clin Oncol 2012(Suppl 5)):abstr 45
   Web of Science ®Google Scholar
• Grimm P, Billiet I, Bostwick D, et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int 2012;109(Suppl 1):22-9
   PubMed Web of Science ®Google Scholar
• Zaorsky NG, Harrison AS, Trabulsi EJ, et al. Evolution of advanced technologies in prostate cancer radiotherapy. Nat Rev Urol 2013;10(10):565-79
   PubMed Web of Science ®Google Scholar
• Yoshioka Y, Nose T, Yoshida K, et al. High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial. Int J Radiat Oncol Biol Phys 2000;48(3):675-81
   PubMed Web of Science ®Google Scholar
• Haynes B. Can it work? Does it work? Is it worth it? The testing of healthcareinterventions is evolving. BMJ 1999;319(7211):652-3
   PubMed Web of Science ®Google Scholar
• Fowler J, Chappell R, Ritter M. Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 2001;50(4):1021-31
   PubMed Web of Science ®Google Scholar
• Park C, Papiez L, Zhang S, et al. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys 2008;70(3):847-52
   PubMed Web of Science ®Google Scholar
• Fowler JF, Ritter MA, Chappell RJ, Brenner DJ. What hypofractionated protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys 2003;56(4):1093-104
   PubMed Web of Science ®Google Scholar
• Brenner DJ, Martinez AA, Edmundson GK, et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002;52(1):6-13
   PubMed Web of Science ®Google Scholar
• Aluwini S, Van Rooij P, Hoogeman M, et al. CyberKnife stereotactic radiotherapy as monotherapy for low- to intermediate-stage prostate cancer: early experience, feasibility, and tolerance. J Endourol 2010;24(5):865-9
   PubMed Web of Science ®Google Scholar
• Katz AJ, Santoro M, Diblasio F, Ashley R. Stereotactic Body Radiation Therapy for Low, Intermediate, and High-risk Prostate Cancer: disease Control and Quality of Life. Int J Radiat Oncol 2011;81(2):S100-0
   Google Scholar
• Katz AJ, Santoro M, Ashley R, et al. Stereotactic body radiotherapy as boost for organ-confined prostate cancer. Technol Cancer Res Treat 2010;9(6):575-82
   PubMed Web of Science ®Google Scholar
• King CR, Brooks JD, Gill H, Presti JCJr. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012;82(2):877-82
   PubMed Web of Science ®Google Scholar
• Mcbride SM, Wong DS, Dombrowski JJ, et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial. Cancer 2012;118(15):3681-90
   PubMed Web of Science ®Google Scholar
• Friedland JL, Freeman DE, Masterson-Mcgary ME, Spellberg DM. Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer. Technol Cancer Res Treat 2009;8(5):387-92
   PubMed Web of Science ®Google Scholar
• Bolzicco G, Favretto MS, Scremin E, et al. Image-guided stereotactic body radiation therapy for clinically localized prostate cancer: preliminary clinical results. Technol Cancer Res Treat 2010;9(5):473-7
   PubMed Web of Science ®Google Scholar
• Kang JK, Cho CK, Choi CW, et al. Image-guided stereotactic body radiation therapy for localized prostate cancer. Tumori 2011;97(1):43-8
   PubMed Web of Science ®Google Scholar
• Zaorsky NG, Studenski MT, Dicker AP, et al. Stereotactic body radiation therapy for prostate cancer: is the technology ready to be the standard of care? Cancer Treat Rev 2013;39(3):212-18
   PubMed Web of Science ®Google Scholar
• Hossain S, Xia P, Chuang C, et al. Simulated real time image guided intrafraction tracking-delivery for hypofractionated prostate IMRT. Med Phys 2008;35(9):4041-8
   PubMed Web of Science ®Google Scholar
• Demanes DJ, Martinez AA, Ghilezan M, et al. High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2011;81(5):1286-92
   PubMed Web of Science ®Google Scholar
• Barkati M, Williams SG, Foroudi F, et al. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial. Int J Radiat Oncol Biol Phys 2012;82(5):1889-96
   PubMed Web of Science ®Google Scholar
• Mark R, Akins RS, Anderson PJ, et al. Interstitial high dose rate (HDR) brachtherapy as monotherapy for early stage prostate cancer: a report of 206 cases. Int J Rad Biol Phys 2007;69(3):S329
   Web of Science ®Google Scholar
• Mark R, Anderson PJ, Akins RS, Nair M. High-Dose-Rate Brachytherapy Under Local Anesthesia for Early Stage Prostate Cancer: A Report of 546 Cases. Brachytherapy 2011;10:S93
   Google Scholar
• Zamboglou N, Tselis N, Baltas D, et al. High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: treatment evolution and mature results. Int J Radiat Oncol Biol Phys 2012;85(3):672-8
   PubMed Web of Science ®Google Scholar
• Ghadjar P, Keller T, Rentsch CA, et al. Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy. Brachytherapy 2009;8(1):45-51
   PubMed Web of Science ®Google Scholar
• Grills IS, Martinez AA, Hollander M, et al. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol 2004;171(3):1098-104
   PubMed Web of Science ®Google Scholar
• Rogers CL, Alder SC, Rogers RL, et al. High dose brachytherapy as monotherapy for intermediate risk prostate cancer. J Urol 2012;187(1):109-16
   PubMed Web of Science ®Google Scholar
• Yoshioka Y, Konishi K, Oh RJ, et al. High-dose-rate brachytherapy without external beam irradiation for locally advanced prostate cancer. Radiother Oncol 2006;80(1):62-8
   PubMed Web of Science ®Google Scholar
• Yoshioka Y, Konishi K, Sumida I, et al. Monotherapeutic high-dose-rate brachytherapy for prostate cancer: five-year results of an extreme hypofractionation regimen with 54 Gy in nine fractions. Int J Radiat Oncol Biol Phys 2011;80(2):469-75
   PubMed Web of Science ®Google Scholar
• Sullivan L, Williams SG, Tai KH, et al. Urethral stricture following high dose rate brachytherapy for prostate cancer. Radiother Oncol 2009;91(2):232-6
   PubMed Web of Science ®Google Scholar
• Ghilezan M, Martinez A, Gustason G, et al. High-dose-rate brachytherapy as monotherapy delivered in two fractions within one day for favorable/intermediate-risk prostate cancer: preliminary toxicity data. Int J Radiat Oncol Biol Phys 2012;83(3):927-32
   PubMed Web of Science ®Google Scholar
• Prada PJ, Jimenez I, Gonzalez-Suarez H, et al. High-dose-rate interstitial brachytherapy as monotherapy in one fraction and transperineal hyaluronic acid injection into the perirectal fat for the treatment of favorable stage prostate cancer: treatment description and preliminary results. Brachytherapy 2012;11(2):105-10
   PubMed Web of Science ®Google Scholar
• Hayes J, Hansen R, Rogers L, et al. Post-treatment PSA Kinetics of three prostate cancer treatment regimens involving brachythe of three prostate cancer treatment regimens involving brachytherapy. Brachytherapy 2006;5(113):P106
   Google Scholar
• Morton G. The best method for dose escalation: prostate brachytherapy. Can Urol Assoc J 2012;6(3):196-8
   PubMed Web of Science ®Google Scholar
• Xie Y, Djajaputra D, King CR, et al. Intrafractional motion of the prostate during hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys 2008;72(1):236-46
   PubMedGoogle Scholar
• Zelefsky MJ, Pei X, Teslova T, et al. Secondary cancers after intensity-modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention. BJU Int 2012;110(11):1696-701
   PubMed Web of Science ®Google Scholar
• Gill S, Li J, Thomas J, et al. Patient-reported complications from fiducial marker implantation for prostate image-guided radiotherapy. Br J Radiol 2012;85(1015):1011-17
   PubMed Web of Science ®Google Scholar
• Taoka R, Togo Y, Kubo T, et al. Assessment of antimicrobial prophylaxis to prevent perioperative infection in patients undergoing prostate brachytherapy: multicenter cohort study. J Infect Chemother 2013;19(5):926-30
   PubMed Web of Science ®Google Scholar
• Nomura T, Hirai K, Yamasaki M, et al. Efficacy of prophylactic single-dose therapy using fluoroquinolone for prostate brachytherapy. Jpn J Radiol 2012;30(4):317-22
   PubMed Web of Science ®Google Scholar
• Arscott WT, Chen LN, Wilson N, et al. Obstructive voiding symptoms following stereotactic body radiation therapy for prostate cancer. Radiat Oncol 2014;9:163
   PubMed Web of Science ®Google Scholar
• Woo JA, Chen LN, Bhagat A, et al. Clinical characteristics and management of late urinary symptom flare following stereotactic body radiation therapy for prostate cancer. Frontiers in oncology 2014;4:122
   PubMedGoogle Scholar
• Baco E, Ukimura O, Rud E, et al. Magnetic resonance imaging-transectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 Patients. Eur Urol 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Aluwini S, Van Rooij P, Hoogeman M, et al. Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results. Radiat Oncol 2013;8:84
   PubMed Web of Science ®Google Scholar
• Jabbari S, Weinberg VK, Kaprealian T, et al. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response. Int J Radiat Oncol Biol Phys 2012;82(1):228-34
   PubMed Web of Science ®Google Scholar
• Mason J, Al-Qaisieh B, Bownes P, et al. Multi-parametric MRI-guided focal tumor boost using HDR prostate brachytherapy: a feasibility study. Brachytherapy 2014;13(2):137-45
   PubMed Web of Science ®Google Scholar
• Pouliot J, Kim Y, Lessard E, et al. Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging. Int J Radiat Oncol Biol Phys 2004;59(4):1196-207
   PubMed Web of Science ®Google Scholar
• Zaorsky NG, Den RB, Doyle LA, et al. Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate cancer. Expert Rev Med Devices 2013;10(6):751-63
   PubMed Web of Science ®Google Scholar
• Shen X, Zaorsky NG, Mishra MV, et al. Comparative effectiveness research for prostate cancer radiation therapy: current status and future directions. Future Oncol 2012;8(1):37-54
   PubMed Web of Science ®Google Scholar
• Konski A. Cost, quality, and value in healthcare: a new paradigm. Oncology (Willston Park) 2010;24(6):542-3
   PubMed Web of Science ®Google Scholar
• Perez CA, Kobeissi B, Smith BD, et al. Cost accounting in radiation oncology: a computer-based model for reimbursement. Int J Radiat Oncol Biol Phys 1993;25(5):895-906
   PubMed Web of Science ®Google Scholar
• Lievens Y, Van Den Bogaert W, Kesteloot K. Activity-based costing: a practical model for cost calculation in radiotherapy. Int J Radiat Oncol Biol Phys 2003;57(2):522-35
   PubMed Web of Science ®Google Scholar
• Norlund A. Costs of radiotherapy. Acta Oncol 2003;42(5-6):411-15
   PubMed Web of Science ®Google Scholar
• Kesteloot K, Lievens Y, Van Der Schueren E. Improved management of radiotherapy departments through accurate cost data. Radiother Oncol 2000;55(3):251-62
   PubMed Web of Science ®Google Scholar
• Van De Werf E, Lievens Y, Verstraete J, et al. Time and motion study of radiotherapy delivery: economic burden of increased quality assurance and IMRT. Radiother Oncol 2009;93(1):137-40
   PubMed Web of Science ®Google Scholar
• Shah C, Lanni TBJr, Ghilezan MI, et al. Brachytherapy provides comparable outcomes and improved cost-effectiveness in the treatment of low/intermediate prostate cancer. Brachytherapy 2012;11(6):441-5
   PubMed Web of Science ®Google Scholar
• Sugihara T, Yasunaga H, Horiguchi H, et al. Comparisons of perioperative outcomes and costs between open and laparoscopic radical prostatectomy: a propensity-score matching analysis based on the Japanese diagnosis procedure combination database. Int J Urol 2013;20(3):349-53
   PubMed Web of Science ®Google Scholar
• Hodges JC, Lotan Y, Boike TP, et al. Cost-effectiveness analysis of stereotactic body radiation therapy versus intensity-modulated radiation therapy: an emerging initial radiation treatment option for organ-confined prostate cancer. J Oncol Pract 2012;8(3 Suppl):e31s-7s
   PubMedGoogle Scholar
• Sher DJ, Parikh R, Mays-Jackson S, Punglia RS. Cost-effectiveness Analysis of SBRT Versus IMRT for Low-risk prostate cancer. Am J Clin Oncol 2012
   Web of Science ®Google Scholar
• Amin NP, Sher DJ, Konski AA. Systematic review of the cost effectiveness of radiation therapy for prostate cancer from 2003 to 2013. Appl Health Econ Health Policy 2014;12(4):391-408
   PubMedGoogle Scholar